Aurobindo Pharma Shares In Focus After Q3 Results; This Brokerage Maintains A Bullish View — More Details Inside

The brokerage noted that Aurobindo is expected to complete the Rs 2,075 crore acquisition of Lannett in Q1 FY27, which may add nearly 7% to FY27 US revenue growth.